Benzoic acid (2R,4aR,6S,7R,8R,8aS)-7-azido-6-((1R,2R,3S,4R,6S)-4,6-diazido-2,3-dihydroxy-cyclohexyloxy)-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yl ester | 918800-26-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Benzoic acid (2R,4aR,6S,7R,8R,8aS)-7-azido-6-((1R,2R,3S,4R,6S)-4,6-diazido-2,3-dihydroxy-cyclohexyloxy)-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yl ester
• CAS: 918800-26-7
• 化学式: C₂₇H₂₉N₉O₉
• 分子量: 623.582
• InChiKey: OEODLRULFITPIT-PXBWZSKISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.61
• 重原子数：
  45.0
• 可旋转键数：
  9.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  259.19
• 氢给体数：
  2.0
• 氢受体数：
  12.0

反应信息

• 作为反应物：
  描述：

  Benzoic acid (2R,4aR,6S,7R,8R,8aS)-7-azido-6-((1R,2R,3S,4R,6S)-4,6-diazido-2,3-dihydroxy-cyclohexyloxy)-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yl ester 在 N-碘代丁二酰亚胺 、 三氟甲磺酸 、 溶剂黄146 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 C₄₅H₄₃N₉O₁₅
  参考文献：
  名称：

  Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations

  摘要：

  A series of new derivatives of the clinically used aminoglycoside antibiotic paromomycin were designed, synthesized, and their ability to read-through premature stop codon mutations was examined in both in vitro translation system and ex vivo mammalian cultured cells. One of these structures, a pseudo-trisaccharide derivative, showed notably higher stop codon read-through activity in cultured cells compared to those of paromomycin and gentamicin. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.013
• 作为产物：
  描述：

  (4a'R,6'S,7'R,8'R,8a'S)-7'-azido-6'-(((3aS,4R,6S,7R,7aS)-4,6-diazidohexahydrospiro[benzo[d][1,3]dioxole-2,1'-cyclohexan]-7-yl)oxy)hexahydrospiro[cyclohexane-1,2'-pyrano[3,2-d][1,3]dioxin]-8'-ol 在 吡啶 、 camphor-10-sulfonic acid 、 三氟乙酸 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 Benzoic acid (2R,4aR,6S,7R,8R,8aS)-7-azido-6-((1R,2R,3S,4R,6S)-4,6-diazido-2,3-dihydroxy-cyclohexyloxy)-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yl ester
  参考文献：
  名称：

  Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations

  摘要：

  A series of new derivatives of the clinically used aminoglycoside antibiotic paromomycin were designed, synthesized, and their ability to read-through premature stop codon mutations was examined in both in vitro translation system and ex vivo mammalian cultured cells. One of these structures, a pseudo-trisaccharide derivative, showed notably higher stop codon read-through activity in cultured cells compared to those of paromomycin and gentamicin. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.013